🇺🇸 United States Country × Condition
ovarian cancer Clinical Trials in United States
Active clinical trials for ovarian cancer with research sites in United States. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 21 // Recruiting: 21 Phases: Phase 1, Phase 1, Phase 2 // Updated: Daily
Total Trials
21
Recruiting Now
21
Country
🇺🇸 United States
Active Trials in United States (21)
NCT06964009 Phase 1
Recruiting
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Enrollment
30 pts
Country
🇺🇸 United States
Elizabeth Stover, MD, PhD
View Trial → NCT05787587 Phase 1
Recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Enrollment
216 pts
Country
🇺🇸 United States
IDEAYA Biosciences
View Trial → NCT00539162
Recruiting
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Enrollment
8,000 pts
Country
🇺🇸 United States
M.D. Anderson Cancer Center
View Trial → NCT05349227
Recruiting
Comprehensive Outcomes for After Cancer Health
Enrollment
625 pts
Country
🇺🇸 United States
Pack Health
View Trial → NCT06646627 Phase 1
Recruiting
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
Enrollment
48 pts
Country
🇺🇸 United States
Stanford University
View Trial → NCT06973161
Recruiting
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Enrollment
105 pts
Country
🇺🇸 United States
AstraZeneca
View Trial → NCT06395519 Phase 1, Phase 2
Recruiting
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Enrollment
120 pts
Country
🇺🇸 United States
858 Therapeutics, Inc.
View Trial → NCT07216105 Phase 1
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Enrollment
113 pts
Country
🇺🇸 United States
Fate Therapeutics
View Trial → NCT07030907 Phase 1
Recruiting
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Enrollment
30 pts
Country
🇺🇸 United States
Outpace Bio, Inc.
View Trial → NCT07225270 Phase 3
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
Enrollment
528 pts
Country
🇺🇸 United States
Genmab
View Trial → NCT04294927
Recruiting
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Enrollment
3,000 pts
Country
🇺🇸 United States
University Medical Center Nijmegen
View Trial → NCT06819007 Phase 3
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Enrollment
582 pts
Country
🇺🇸 United States
Daiichi Sankyo
View Trial → NCT06580002 Phase 2
Recruiting
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Enrollment
51 pts
Country
🇺🇸 United States
University of California, Irvine
View Trial → NCT06760507
Recruiting
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
Enrollment
3,209 pts
Country
🇺🇸 United States
Emory University
View Trial → NCT05316129 Phase 1
Recruiting
Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
Enrollment
10 pts
Country
🇺🇸 United States
H. Lee Moffitt Cancer Center and Re...
View Trial → NCT06342986 Phase 1
Recruiting
Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Enrollment
33 pts
Country
🇺🇸 United States
Masonic Cancer Center, University o...
View Trial → NCT06321484 Phase 1
Recruiting
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Enrollment
18 pts
Country
🇺🇸 United States
Dana-Farber Cancer Institute
View Trial → NCT06276491 Phase 1
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Enrollment
282 pts
Country
🇺🇸 United States
Xencor, Inc.
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇺🇸 United States
PMV Pharmaceuticals, Inc
View Trial → NCT06366490 Phase 1
Recruiting
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer
Enrollment
8 pts
Country
🇺🇸 United States
PhotonPharma, Inc.
View Trial → NCT06234423 Phase 1
Recruiting
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Enrollment
263 pts
Country
🇺🇸 United States
OnCusp Therapeutics, Inc.
View Trial → Frequently Asked Questions
How many ovarian cancer clinical trials are active in United States?
There are currently 21 active clinical trials for ovarian cancer with sites in United States, of which 21 are actively recruiting patients.
How can I join a ovarian cancer clinical trial in United States?
To join a ovarian cancer clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are ovarian cancer trials in United States?
Active ovarian cancer trials in United States span Phase 1, Phase 1, Phase 2, Phase 3, Phase 2. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.